FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference
January 10, 2023 06:00 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific...
Muscular Dystrophy Association Elects Governor Brad Henry as Chairman and Christopher Rosa, Ph.D. as Vice Chairman of the Board of Directors
January 09, 2023 09:20 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership. Governor Brad Henry will now serve as...
Eledon Pharmaceuticals Provides Business and Pipeline Updates
January 09, 2023 08:31 ET
|
Eledon Pharmaceuticals, Inc.
Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Continued enrollment in open-label Phase 1b kidney transplant trial with initial data...
Athira Pharma Provides 2023 Pipeline Outlook
January 05, 2023 07:00 ET
|
Athira Pharma, Inc.
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase...
Le masitinib reçoit la désignation de médicament orphelin pour le traitement de la sclérose latérale amyotrophique en Suisse
December 27, 2022 13:04 ET
|
AB Science
COMMUNIQUE DE PRESSE LE MASITINIB REÇOIT LA DÉSIGNATION DE MÉDICAMENT ORPHELIN POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) EN SUISSE Paris, 26 décembre 2022, 19h AB Science SA...
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
December 27, 2022 13:04 ET
|
AB Science
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA (Euronext - FR0010557264...
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
December 21, 2022 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
December 05, 2022 07:30 ET
|
Athira Pharma, Inc.
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS Data adds to the growing body of evidence...
Major investment in top talent in ALS research
November 24, 2022 09:00 ET
|
ALS Society of Canada
Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS)...
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
November 14, 2022 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S....